Nasdaq vktx.

About Institutional Holdings. Nasdaq provides the ownership stake information in a company, including the number of shares held by those institutions in a firm, along with recent purchases and ...Viking Therapeutics, Inc. (NASDAQ:VKTX) insiders who bought shares over the past year were rewarded handsomely last week. The stock rose 8.7%, resulting in a US$167m rise in the company's market ...Shares of Viking Therapeutics (NASDAQ:VKTX) are making headlines this week after an announcement from Gilead Sciences (NASDAQ:GILD), that one of its drugs did not meet the primary endpoints of its ...Viking Therapeutics, Inc. (NASDAQ:VKTX) insiders who bought shares over the past year were rewarded handsomely last week.The stock rose 8.7%, resulting in a US$167m rise in the company's market ...

Pfizer (NYSE:PFE) shares hit a new 52-week low on Friday after announcing that its twice-daily oral weight loss candidate danuglipron will not reach late-stage development as a Phase 2 readout ...

SAN DIEGO, Nov. 2, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...Apr 4, 2023 · Find out why VKTX stock is a Buy. ... (NASDAQ:VKTX). As you know, Viking shares recently rallied over 60% in a single trading session due to its positive early obesity data. Though Viking executed ...

Viking Therapeutics, Inc. Common Stock (VKTX) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.Dec 1, 2023 · In the previous quarter, Viking Therapeutics (NASDAQ:VKTX) missed the analysts' consensus estimate of ($0.22) by $0.01 with a reported earnings per share (EPS) of ($0.23). Learn more on analysts' earnings estimate vs. VKTX's actual earnings. Viking Therapeutics, Inc. (VKTX) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 13.01 +0.79 (+6.46%) At close: 04:00PM EST. 13.10 +0.09 (+0.69%) After hours: 07:47PM EST.Apr 16, 2023 · VIKING THERAPEUTICS INC ( VKTX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 94% based on the firm’s underlying fundamentals and the stock ... Study Enrollment and Dosing to Resume. SAN DIEGO, July 19, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the FDA has lifted the clinical hold …

Mar 30, 2023 · Shares of Viking Therapeutics ( VKTX 6.23%) were up 89.7% for the week as of Thursday afternoon, after being up as much as 95.5% for the week, according to data provided by S&P Global Market ...

Nov 28, 2023 · Stock analysis for Viking Therapeutics Inc (VKTX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Viking Therapeutics Inc (NASDAQ: VKTX) (after the close) Thursday . Evelo Biosciences Inc (NASDAQ: EVLO) (before the market open) Baxter International Inc (NYSE: BAX) (before the market open)The "Mad Money" host said Viking Therapeutics, Inc. (NASDAQ:VKTX) is a "very good spec, but you have to understand it could be wiped out or go up a lot." Price Action: ...Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of new results from the ongoing Phase 2b clinical trial of VK2809, the company's novel liver-selective thyroid hormone receptor …Nasdaq Data provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. Data Link's cloud-based technology platform allows you to search, discover and access ...Viking Therapeutics, Inc. (NASDAQ: VKTX) is an American biotechnology company that is focused on the development of novel and orally available therapies for the treatment of metabolic and ...The largest stake in Viking Therapeutics, Inc. (NASDAQ:VKTX) was held by Park West Asset Management, which reported holding $7.5 million worth of stock at the end of September.It was followed by ...

SAN DIEGO, July 27, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX ), a clinical-stage biopharmaceutical company focused on the development of novel therapies for ...Strong Quarter-End Cash Position of $376M. SAN DIEGO, Oct. 25, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the ...5 Best Weight Loss Stocks To Invest In Viking Therapeutics, Inc. (NASDAQ:VKTX) Q2 2023 Earnings Call Transcript 10 Stocks Wall Street Analysts and Billionaires Are Crazy About 15 Best-Performing ...Pfizer (NYSE:PFE) shares hit a new 52-week low on Friday after announcing that its twice-daily oral weight loss candidate danuglipron will not reach late-stage development as a Phase 2 readout ...SAN DIEGO, Nov. 19, 2019 /PRNewswire/ -- Viking Therapeutics Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a Phase 2b clinical trial of VK2809, its novel liver-selective thyroid hormone receptor beta agonist, …

Dec 1, 2023 · During the last session, Viking Therapeutics Inc (NASDAQ:VKTX)’s traded shares were 1.77 million, with the beta value of the company hitting 0.59. At the end of the trading day, the stock’s price was $12.22, reflecting an intraday gain of 3.30% or $0.39. The 52-week high for the VKTX share is $ ...

VKTX U.S.: Nasdaq Viking Therapeutics Inc. Watch NEW Set a price target alert After Hours Last Updated: Dec 1, 2023 7:47 p.m. EST Delayed quote $ 13.10 0.09 0.69% After …View real-time VKTX stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ... Study Enrollment and Dosing to Resume. SAN DIEGO, July 19, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the FDA has lifted the clinical hold …Find real-time VKTX - Viking Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.EPS Estimate Trends. Current. N/A. 1 Month Ago. -$0.24. 3 Months Ago. -$0.24. Viking Therapeutics Inc. analyst estimates, including VKTX earnings per share estimates and analyst recommendations.November 28, 2023. Technologies. In the last trading session, 1.46 million shares of the Viking Therapeutics Inc (NASDAQ:VKTX) were traded, and its beta was 0.61. Most recently the company’s share price was $12.00, and it changed around -$0.28 or -2.28% from the last close, which brings the market valuation of the company to $1.20B.VIKING THERAPEUTICS INC ( VKTX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 55% based on the firm’s underlying fundamentals and the stock ...

Find the latest Earnings Report Date for Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com.

Viking Therapeutics (NASDAQ:VKTX) shares gained over 5% in extended trading on Monday after the drugmaker reported positive findings from an ongoing study of its lead drug candidate, VK2809.VK2809 ...

Viking Therapeutics Inc. (NASDAQ: VKTX) Viking Therapeutics was founded in 2012 to create treatments for metabolic and endocrine disorders. This area still has a lot of need, and FDA approval here could catapult the company forward on its own.Market Cap. $1.3B. Currency in USD. Quote data delayed by at least 15 minutes.Viking Therapeutics, Inc. (VKTX.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Viking Therapeutics, ...If you’re familiar with investing, then you’ve probably heard of major stock exchanges like the New York Stock Exchange or the NASDAQ. Stock exchanges are sort of like a mixture between an auction house and a marketplace where investors can...SAN DIEGO, July 2, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...According to the issued ratings of 9 analysts in the last year, the consensus rating for Viking Therapeutics stock is Buy based on the current 9 buy ratings for VKTX. The average twelve-month price prediction for Viking Therapeutics is $30.25 with a high price target of $37.00 and a low price target of $19.00.(NASDAQ: VKTX) Viking Therapeutics's market cap is $978.28M, as of Nov 12, 2023. Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares. Viking Therapeutics 's market cap is calculated by multiplying VKTX 's current stock price of $9.78 by VKTX 's total outstanding shares of 100,028,953 .InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Viking Therapeutics (NASDAQ:VKTX) stock is taking off o... InvestorPlace - Stock Market News, Stock Advice & Trading Tips Viking Therapeutics (NASDAQ...Mar 28, 2023 · Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP agonist compound VK2735 for the ... Viking Therapeutics (NASDAQ:VKTX) spiked in late December, due to recent news indirectly related to the biopharma firm, and its efforts to bring a treatment for non-alcoholic steatohepatitis (or ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...SAN DIEGO, Feb. 8, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2022, and provided an update on its clinical …Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock. SAN DIEGO , March 29, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic a... 8 months ago - PRNewsWire.Instagram:https://instagram. goldman sachs business credit cardb2b training programspure storage earningsskyline champion Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have received an average rating of “Buy” from the nine analysts that are presently covering the stock, MarketBeat Ratings reports. Nine analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have covered the stock in the […] which is the best sandp 500 index fundhealth insurance providers in arizona Today's Change. (1.85%) $0.21. Current Price. $11.56. Price as of November 22, 2023, 4:00 p.m. ET. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium ...For Viking Therapeutics (NASDAQ: VKTX) that’s exactly what investors get. VKTX has currently five drugs in its development pipeline. Those drugs are targeting a variety of diseases including ... better mortgage stock price VKTX U.S.: Nasdaq Viking Therapeutics Inc. Watch NEW Set a price target alert After Hours Last Updated: Dec 1, 2023 7:47 p.m. EST Delayed quote $ 13.10 0.09 0.69% After …About Latest Pre-Market Trades. Nasdaq provides market information opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. See Also. Nasdaq MarketSIte. Do Not Sell …Research Viking Therapeutics' (Nasdaq:VKTX) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance ...